Ignite Creation Date:
2024-05-06 @ 10:50 AM
Last Modification Date:
2024-10-26 @ 12:36 PM
Study NCT ID:
NCT03365648
Status:
COMPLETED
Last Update Posted:
2018-11-15
First Post:
2017-11-22
Brief Title:
Efficacy and Safety of Lertal as an add-on to Standard Therapy for Allergic Rhinoconjunctivitis in Pediatrics
Sponsor:
NTC srl
Organization:
NTC srl
Study Overview
Official Title:
A Randomized Double-blinded Parallel-group Placebo-controlled Clinical Study of the Efficacy and Safety of an Oral Nutraceutical Lertal as an add-on to Standard Therapy for Allergic Rhinoconjunctivitis in Pediatrics
Status:
COMPLETED
Status Verified Date:
2018-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of Lertal as an add-on treatment for children affected by allergic rhinoconjunctivitis
Detailed Description:
Allergic rhinoconjunctivitis AR is a common chronic disorder in children especially in developed countries It is not characterized by nasal symptoms only such as congestion and sneezing but may also cause general complaints such as fatigue and cough AR can also have detrimental effects on mood sleep social activities and scholastic performance
Lertal is a novel nutraceutical containing seed extracts from Perilla Frutescens Quercetin extracted from Sophora japonica and Vitamin D3 all compounds that have demonstrated their ability to reduce allergy symptoms and the use of anti-allergy drugs in adults
The aim of this randomized double-blinded parallel-group placebo-controlled study is to evaluate the efficacy and safety of Lertal as an add-on treatment for children affected by allergic rhinoconjunctivitis
Lertal is a novel nutraceutical containing seed extracts from Perilla Frutescens Quercetin extracted from Sophora japonica and Vitamin D3 all compounds that have demonstrated their ability to reduce allergy symptoms and the use of anti-allergy drugs in adults
The aim of this randomized double-blinded parallel-group placebo-controlled study is to evaluate the efficacy and safety of Lertal as an add-on treatment for children affected by allergic rhinoconjunctivitis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None